<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00536913</url>
  </required_header>
  <id_info>
    <org_study_id>D5897C00004</org_study_id>
    <nct_id>NCT00536913</nct_id>
  </id_info>
  <brief_title>Evaluation of Safety and Efficacy of Symbicort® pMDI, With or Without Spacer, in Children (6-11 Years) With Asthma</brief_title>
  <acronym>Spacer</acronym>
  <official_title>A 4-week, Open-label, Randomized, Multi-centre, Parallel-group Study Evaluating the Safety and Efficacy of 4 Actuations Symbicort® (Budesonide/Formoterol) HFA pMDI 40/2.25 μg Twice Daily, With and Without Spacer, in Children (6-11 Years) With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare Symbicort pMDI with and without spacer in terms of
      steroid potency, improvement of lung function and asthma symptoms in children with asthma
      (6-11 years).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Free Cortisol (UFC)</measure>
    <time_frame>At baseline and 4 weeks</time_frame>
    <description>Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>At baseline, at 2 weeks and 4 weeks</time_frame>
    <description>Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Peak Expiratory Flow (mPEF)</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evening Peak Expiratory Flow (ePEF)</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptoms at Night</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptoms at Day</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Nights With Awakenings Due to Asthma</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication at Night</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication at Day</measure>
    <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
    <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>With Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without Spacer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol pMDI 40/2.25ug + spacer</intervention_name>
    <arm_group_label>With Spacer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide/formoterol pMDI 40/2.25 ug</intervention_name>
    <arm_group_label>Without Spacer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  children 6-11 years, diagnosed asthma treated

          -  6 months, PEF

          -  50% of predicted normal value pre-bronchodilator

        Exclusion Criteria:

          -  current systemic glucocorticosteroids usage

          -  current respiratory infection

          -  any significant disease or disorder as judged by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomas Anderson, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Piotr Kuna, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uniwersytecki Spital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaposvar</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Karpacz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2007</study_first_submitted>
  <study_first_submitted_qc>September 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2007</study_first_posted>
  <results_first_submitted>February 16, 2009</results_first_submitted>
  <results_first_submitted_qc>January 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 27, 2012</results_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symbicort pMDI</keyword>
  <keyword>spacer</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>137 subjects enrolled; 30 non randomised: 26 failed inclusion criteria, 2 voluntary discontinuations, 1 incorrect enrolment, 1 adverse event. 107 subjects were randomised</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>With Spacer</title>
          <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
        </group>
        <group group_id="P2">
          <title>Without Spacer</title>
          <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>With Spacer</title>
          <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
        </group>
        <group group_id="B2">
          <title>Without Spacer</title>
          <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="52"/>
            <count group_id="B3" value="107"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="B2" value="8.9" lower_limit="6" upper_limit="11"/>
                    <measurement group_id="B3" value="8.7" lower_limit="6" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urinary Free Cortisol (UFC)</title>
        <description>Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment</description>
        <time_frame>At baseline and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Free Cortisol (UFC)</title>
          <description>Ratio between the value at the end of treatment and the value at start of treatment, including only patients with values at both baseline and end of treatment</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" lower_limit="0.20" upper_limit="2.4"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.12" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.</description>
        <time_frame>At baseline, at 2 weeks and 4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Changes in FEV1 from baseline to the mean value at 2 weeks to 4 weeks with the baseline value as a covariate.</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="-0.38" lower_limit="-0.38" upper_limit="0.76"/>
                    <measurement group_id="O2" value="0.14" spread="-0.34" lower_limit="-0.34" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Peak Expiratory Flow (mPEF)</title>
        <description>Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Peak Expiratory Flow (mPEF)</title>
          <description>Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry were estimated using linear interpolation.</description>
          <units>Liters/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.70" spread="24.6"/>
                    <measurement group_id="O2" value="19.50" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evening Peak Expiratory Flow (ePEF)</title>
        <description>Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Evening Peak Expiratory Flow (ePEF)</title>
          <description>Change in average value from the run-in to the treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation. Missing data between the first and last entry were estimated using linear interpolation.</description>
          <units>Liters/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.00" spread="27.7"/>
                    <measurement group_id="O2" value="15.30" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptoms at Night</title>
        <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptoms at Night</title>
          <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.46"/>
                    <measurement group_id="O2" value="-0.21" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptoms at Day</title>
        <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptoms at Day</title>
          <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation. Daily scale:0 = No symptoms; 1 = Mild symptoms; 2 = Moderate symptoms; 3 = Severe symptoms.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.43"/>
                    <measurement group_id="O2" value="-0.28" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Nights With Awakenings Due to Asthma</title>
        <description>Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Nights With Awakenings Due to Asthma</title>
          <description>Change in Percentage of nights with awakenings, average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
          <units>Percentage of nights</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.80" spread="27.2"/>
                    <measurement group_id="O2" value="-8.20" spread="23.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication at Night</title>
        <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication at Night</title>
          <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
          <units>Inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.21" spread="0.50"/>
                    <measurement group_id="O2" value="-0.14" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Medication at Day</title>
        <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
        <time_frame>Daily during run-in and daily during treatment period of 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>With Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
          </group>
          <group group_id="O2">
            <title>Without Spacer</title>
            <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Medication at Day</title>
          <description>Change in average value from the run-in to treatment period, calculated using all available data for the 10 last days of run-in, and all available data after randomisation.Missing data between the first and last entry estimated using linear interpolation.</description>
          <units>Inhalations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.56"/>
                    <measurement group_id="O2" value="-0.19" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>With Spacer</title>
          <description>Budesonide/formoterol pMDI 40/2.25ug + spacer</description>
        </group>
        <group group_id="E2">
          <title>Without Spacer</title>
          <description>Budesonide/formoterol pMDI 40/2.25 ug</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

